1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Press Officer and Head of Press and Public Relations

Dr. Stefanie Seltmann
Dr. Stefanie Seltmann

Im Neuenheimer Feld 280
69120 Heidelberg

Phone: +49 6221 422854
Fax: +49 6221 422968

E-Mail: s.seltmann@dkfz.de
or presse@dkfz.de

Recent Press Releases

No. 30 | 02. July 2015 | by Sel

Wolfgang Wick will be the new Chairman and Scientific Member of the Management Board of the German Cancer Research Center

Wolfgang Wick will be the new Chairman and Scientific Member of the Management Board of the German Cancer Research Center

Professor Wolfgang Wick has been appointed today by the board of trustees as the new Scientific Director and Chairman of the Management Board of the German Cancer Research Center (DKFZ). He will succeed Professor Otmar D. Wiestler who will leave the DKFZ for the position of the president of the Helmholtz-Association in Berlin at September 1, 2015.

No. 28 | 02. July 2015 | by ms

Large publicity campaign for Cancer Information Service launched

Large publicity campaign for Cancer Information Service launched

For many cancer patients and their families, the Cancer Information Service (KID) at the German Cancer Research Center (DKFZ) is an important resource for all questions concerning cancer. People from all over Germany use the service; however, most users are from the southern German state of Baden-Württemberg and its neighboring states. In order to make the Cancer Information Service more widely known throughout Germany, the DKFZ will launch a major campaign consisting of posters, TV spots and online banners in 2015.

No. 26 | 22. June 2015 | by Koh

Award-winning agent developed for prostate cancer diagnosis and treatment

Award-winning agent developed for prostate cancer diagnosis and treatment

Joint Press Release by the German Cancer Research Center and Heidelberg University Hospital
Scientists at the German Cancer Research Center (DKFZ) have developed an agent called PSMA-617, which is capable of attaching specifically to prostate cancer cells. This agent can be labeled with various radioactive substances. When chemically bound to a weakly radioactive diagnostic radionuclide, it can detect prostate tumors and their metastases in PET scans. If labeled with a strongly radioactive therapeutic radionuclide, PSMA-617 can specifically destroy cancer cells. A first clinical application of this radiopharmaceutical at Heidelberg University Hospital has now delivered promising results.

Audio (in German only)
einblick (in German only)
Publications
Videos (in German only)
last update: 16/10/2013 back to top